Introduction {#s1}
============

Obstructive sleep apnea (OSA) is a serious widespread disease in which upper airways undergo repeated occlusions and arterial oxygen saturation (SaO~2~) repeatedly falls during sleep. OSA defined by a number of significant apnea/hypopnea index episodes ≥5 per hour, is estimated to occur in approximately 24% of men and 9% of women in the general population [@pone.0061382-Young1]. OSA is a risk factor for cardiovascular disease and type 2 diabetes [@pone.0061382-Bradley1], [@pone.0061382-Pamidi1]. All these diseases are predicted by weight gain [@pone.0061382-Peppard1], but whether the association of OSA with diabetes is due to the coexisting obesity, this remains to be determined [@pone.0061382-Pamidi1].

In 2008 the International Diabetes Federation recommended to raise awareness of possible OSA in patients with type 2 diabetes as well as to look for metabolic disorders in patients with OSA [@pone.0061382-Shaw1]. This recommendation was built on the high prevalence of type 2 diabetes in patients with OSA and on the direct relation between glucose tolerance and OSA severity ([@pone.0061382-Pamidi1] for review). Several cross-sectional and longitudinal studies, however, were unable to conclude unequivocally that OSA is an independent risk factor for diabetes [@pone.0061382-Pamidi1], [@pone.0061382-Reichmuth1], [@pone.0061382-Botros1]. Furthermore, in type 2 diabetic patients with OSA who underwent lifestyle intervention, changes in glucose control were determined by changes in weight rather than in AHI [@pone.0061382-Foster1] and the beneficial effects of CPAP treatment on glucose tolerance are controversial [@pone.0061382-Pamidi1].

Similarly to what observed for type 2 diabetes, the prevalence of impaired fasting glucose (IFG) and of impaired glucose tolerance (IGT) increase with the severity of OSA [@pone.0061382-Seicean1]--[@pone.0061382-Togeiro1]. These prediabetic states are characterized by a decrease in insulin sensitivity which has been independently associated with the presence and severity of OSA in several population and clinic-based cross-sectional studies [@pone.0061382-Pamidi1], [@pone.0061382-Togeiro1], [@pone.0061382-Bulcun1]. Other studies however, reported that in OSA patients insulin resistance and metabolic syndrome are determined by obesity rather than by the characteristic sleep breathing disorder [@pone.0061382-Davies1]--[@pone.0061382-Sharma1]. Besides obesity, other factors like age and gender may confound the relation of OSA with glucose homeostasis. For example, most studies have been conducted in men because they suffer more frequently of sleep-disordered breathing [@pone.0061382-Young1]. However, men and women are alike for the role of abdominal obesity on metabolic consequences as well as for alterations in insulin sensitivity and in glucose control [@pone.0061382-Blaak1], [@pone.0061382-Franzini1].

Strategies to modify lifestyle habits are encouraged for the treatment of sleep-disordered breathing and very low energy diets or bariatric surgery have been shown to reduce AHI by 40 and 70% respectively [@pone.0061382-Tuomilehto1], [@pone.0061382-Haines1]. To date studies evaluating the effects of a moderate weight loss, easy to implement in the clinical practice, in ameliorating cardiovascular risk factors in OSA are few. Furthermore, most of these studies were carried out in men and showed doubtful benefits in women ([@pone.0061382-Anandam1] for review).

Therefore given that 1) uncertainty exists concerning the independent association of OSA with abnormal glucose tolerance particularly in women [@pone.0061382-TheorellHaglw1], [@pone.0061382-Bixler1]; 2) the relation between changes in glucose tolerance and in OSA severity after weight loss has been poorly investigated, we analyzed whether OSA is associated with impaired glucose homeostasis in premenopausal (PM) and menopausal (M) non diabetic obese women. The relationship between changes in nocturnal polysomnographic data and glucose homeostasis after a 3-month lifestyle intervention were also examined.

Patients and Methods {#s2}
====================

Ethic Statement {#s2a}
---------------

The study was approved by the Ethics Committee of Istituto Auxologico Italiano, and written informed consent was obtained from all subjects after a full explanation of the study methods and purposes.

The study sample consisted in 98 Caucasian non diabetic obese women consecutively recruited during the second half of 2010 from those referred to the Istituto Auxologico Italiano for a weight-loss lifestyle intervention. We enrolled non diabetic women because the relationships of OSA with alterations in glucose homeostasis are less likely to be blurred by confounding factors as in the overt diabetes.

In all women, information on smoking habits, use of medications and family history of diabetes was collected. Menopausal status was defined by self-reported amenorrhea for at least 12 months.

Excessive daytime somnolence was assessed before and after the intervention using the Epworth Sleepiness Scale [@pone.0061382-Johns1], with a score threshold of more than 10 been taken as suggestive for excessive daytime somnolence.

Before and 3 months after lifestyle intervention, anthropometric measures, blood pressure (BP) and heart rate were measured and body composition assessed by bioelectric impedance assay (BIA 101-RJL Systems Akern srl, Firenze, Italy). The neck circumference was measured just below the laryngeal prominence and waist circumference at the level of the umbilicus. The oral glucose tolerance test (OGTT) was performed with the measurement of glucose and insulin and a fasting blood sample taken for C-reactive protein (CRP) measurements. Insulin sensitivity was estimated using the OGTT-derived insulin sensitivity index (ISI) which is a marker of whole body (muscle plus liver) insulin sensitivity and strongly correlates with the results obtained with the euglycemic insulin clamp [@pone.0061382-Matsuda1]. ISI was computed according to the formula: 10000/√ ((fasting glucose×fasting insulin)×((glucose0\*15+ glucose30\*30+glucose60\*30+glucose90\*30+glucose120\*15)/120)×((insulin0\*15+insulin30\*30+insulin60\*30+insulin90\*30+insulin120\*15)/120)). Beta cell function was determined by the insulinogenic index (ΔI~30~/ΔG~30~) expressed as the ratio of the incremental (0--30 min) insulin and glucose response to OGTT [@pone.0061382-Phillips1]. Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) were defined using the American Diabetes Association criteria. Clinic BP was measured in a sitting position, three times every 5 min with a standard mercury sphygmomanometer and a cuff size optimized for arm circumference. Phase I and V (disappearance) Korotkoff sounds were used to identify systolic and diastolic BP. Obese women were classified as hypertensive if they had clinic BP\>140/90 or were on antihypertensive therapy.

Lifestyle intervention lasted 3 months and consisted in weekly visits to our center for nutritional education, advice reinforcement on exercise activity and peer group psychological support. A self-monitor diary including food consumption, daily physical activity and emotional reactions was used as a tool for education and reinforcement. Daily caloric requirements were calculated by using the Harris-Benedict equation and an individual activity factor. Diet instructions based on a 750-kcal/d deficit from estimated caloric requirement (1200--2000 kcal/day) were given by a dietician to each subject. Diet included 17--22% of total energy intake as protein, 23--25% as fat and 55--58% as carbohydrate. A physical activity program was prescribed consisting in 210 minutes per week (70% of moderate-intensity aerobic physical activity and 30% of muscle-strengthening activities).

Biochemical Measurements {#s2b}
------------------------

Circulating levels of glucose were measured using an automated analyzer (Roche Diagnostic, Manheim, Germany). Insulin was measured by Electrochemiluminescence ImmunoAssay (Roche Diagnostic, Monza, Italy) with a detection limit of 0.2 mU/L and intra- and inter-assay CV of 0.9% and 3.4%, respectively. CRP concentrations were measured by immunoturbidimetric assay (Roche Diagnostics, Monza, Italy) with a detection limit of 0.3 mg/L and intra- and inter-assay CV of 1.1% and 3.3%.

Ambulatory Nocturnal Polysomnography (Cardio-respiratory Monitoring) {#s2c}
--------------------------------------------------------------------

All obese women underwent ambulatory nocturnal polysomnography before and after 3 months of lifestyle intervention. For at least 8 hours, including at least 4 hours of sleep, the following parameters were recorded: ECG, nasal airflow, thoracic and abdominal effort, oxygen saturation by pulse oximetry, snoring and body position. An OSA event was defined as a period of 10 or more seconds of complete nasal airflow cessation during sleep; hypopnea as a period equal to or longer than 10 seconds of discernible reduction in airflow, accompanied by a SaO2 reduction ≥4%. According to International Guidelines OSA is considered mild when AHI is between 5 and 15, moderate with an AHI between 15 and 30 and severe when AHI is above 30 events per hour [@pone.0061382-Iber1].

Statistical Analyses {#s2d}
--------------------

Variables that were not normally distributed were log transformed for the analysis.

To minimize the possible positive effects of height on cardio-metabolic morbidity, in the analyses we used the waist-to-height ratio (WHR), as well as the neck-to-height ratio (NHR). Two sample t-tests and ANCOVA were used to examine the differences between groups. Frequencies were compared using a χ^2^ test. Pearson correlation analyses were used to evaluate bivariate relationships. Partial Correlations procedure was used to describe the linear relationship between two variables while controlling for the effects of one or more additional variables.

Multivariate regression analysis was performed using variables statistically significant at the 5% level in univariate analysis. Changes induced by lifestyle intervention were calculated as the ratio between 3-month value less baseline value and baseline value. Test t for one sample was used to analyze changes from baseline. A probability value \<0.05 was considered significant. Data are given as the means ± SD unless otherwise stated. All analyses were performed using SPSS version 19.0 (SPSS, Chicago, IL, US).

Results {#s3}
=======

Fifty four obese women (55.1%) had OSA that was mild in 70.4%, moderate in 25.9% and severe in 3.7%. [Table 1](#pone-0061382-t001){ref-type="table"} summarizes the clinical characteristics of PM and M obese women participating in the study. Compared to PM women, M women had higher levels of NHR and WHR (NHR: 0.24±0.02 vs 0.23±0.02; WHR 0.73±0.06 vs 0.69±0.06, p\<0.05 for both) and a higher prevalence of OSA (64% vs 41%, p\<0.05). M women had a worse glucose homeostasis (higher fasting glucose, 2 h glucose and lower insulinogenic index) than PM women only in non OSA groups. In OSA group glucose tolerance was comparable between PM and M women.

10.1371/journal.pone.0061382.t001

###### Clinical, anthropometric, metabolic variables and nocturnal respiratory registration data in PM and M obese women according to the presence of OSA.

![](pone.0061382.t001){#pone-0061382-t001-1}

                                    Premenopausal women (n = 39)                       Menopausal women (n = 59)                                
  ------------------------- --------------------------------------------- ---------------------------------------------------- ---------------- ---------------------------------------------------
  Age, yrs                                    37.5±9.5                                         *41.7±8.0*                          58.5±8.4         *62.9±6.1* [a](#nt102){ref-type="table-fn"}
  FH of diabetes, %                             59.0                                             *25.0*                              61.9                             *36.8*
  BMI, kg/m2                  36.0±3.4[§](#nt105){ref-type="table-fn"}        *39.5±4.8* [a](#nt102){ref-type="table-fn"}          33.5±3.3         *36.8±3.7* [b](#nt103){ref-type="table-fn"}
  Current smokers,%                             13.6                                             *6.3*                               23.8                             *10.8*
  Waist/height                                0.68±0.05                       *0.72±0.06* [a](#nt102){ref-type="table-fn"}        0.71±0.05        *0.74±0.06* [a](#nt102){ref-type="table-fn"}
  Neck/height                                 0.23±0.02                                       *0.23±0.02*                         0.23±0.02                         *0.24±0.01*
  Fat mass/fat free mass                       0.9±0.2                                         *1.0±0.2*                           0.9±0.2                           *1.0±0.2*
  Systolic BP, mmHg                          128.2±20.3                                       *125.6±8.9*                         129.3±11.8                       *131.2±12.2*
  Diastolic BP, mmHg                          81.0±10.5                                        *80.6±4.4*                          78.1±7.3                         *80.8±7.0*
  Heart rate, b/min                           77.1±8.3                                        *81.1±13.5*                          78.6±9.4                         *74.4±9.6*
  Fasting glucose, mg/dl      84.9±6.9[§](#nt105){ref-type="table-fn"}        *96.1±9.1* [c](#nt104){ref-type="table-fn"}         95.0±12.3                         *93.6±9.6*
  2 h glucose, mg/dl          98.8±24.3[§](#nt105){ref-type="table-fn"}      *116.1±22.2* [a](#nt102){ref-type="table-fn"}        122.0±43.4                       *115.1±35.0*
  ISI, mg/dl                                  9.2.3±6.4                        *6.1±3.7* [a](#nt102){ref-type="table-fn"}          6.6±4.5                           *6.7±4.7*
  ΔI~30~/ΔG~30~,pmol/mmol    282.0±204.9[§](#nt105){ref-type="table-fn"}                      *199.9±90.5*                        111.2±76.3                       *147.1±110.8*
  CRP, mg/dl ^∧^                           0.4 (0.2--0.7)                  *0.9 (0.2--2.2)* [\#](#nt107){ref-type="table-fn"}   0.4 (0.1--0.5)   *0.5 (0.3--0.7)* [b](#nt103){ref-type="table-fn"}
  IFG/IGT, %                                    0/8.7                       *18.8* [b](#nt103){ref-type="table-fn"} */12.5*        4.7/23.8                         *21.1/13.2*
  Hypertension, %                               21.7                            *31.3* [\#](#nt107){ref-type="table-fn"}             47.6             *78.9* [a](#nt102){ref-type="table-fn"}
  ESS score                                    5.7±4.0                                         *8.3±5.3*                           6.9±4.8                           *4.6±3.0*
  AHI                         0.8±1.1[§§](#nt106){ref-type="table-fn"}        *16.1±10.6* [a](#nt102){ref-type="table-fn"}         1.9±1.3          *14.4±7.9* [c](#nt104){ref-type="table-fn"}
  ODI                         1.2±1.2[§§](#nt106){ref-type="table-fn"}        *14.7±10.1* [c](#nt104){ref-type="table-fn"}         2.6±1.4          *14.2±8.5* [c](#nt104){ref-type="table-fn"}
  Mean SaO~2~,%               96.1±1.3[§§](#nt106){ref-type="table-fn"}       *93.9±1.7* [c](#nt104){ref-type="table-fn"}          94.5±1.2         *93.7±1.4* [a](#nt102){ref-type="table-fn"}
  Minimal SaO~2~,%            90.0±3.2[§](#nt105){ref-type="table-fn"}        *82.2±7.6* [c](#nt104){ref-type="table-fn"}          88.0±2.1         *80.9±4.7* [c](#nt104){ref-type="table-fn"}

FH: family history; BMI: body mass index; BP: blood pressure; IFG: impaired fasting glucose; IGT: impaired glucose tolerance; ISI: insulin sensitivity index; ΔI~30~/ΔG~30:~ insulinogenic index; CRP: C- reactive protein; ESS: Epworth Sleepiness Scale; AHI: Apnea-Hypopnea Index; ODI: Oxygen Desaturation Index; SaO~2~: nocturnal oxygen saturation. Data are expressed as mean ± SD except for CRP which is expressed as median (interquartile range).

p\<0.05,

p\<0.01,

p\<0.0001 OSA vs no OSA women;

p\<0.05,

p\<0.001 no OSA premenopausal vs no OSA menopausal women;

p\<0.01 premenopausal OSA vs menopausal OSA women.

We then analyzed the differences between OSA and non OSA women separately in PM and M group. Among PM women, those with OSA had lower ISI and higher fasting glucose, 2 h glucose and IFG prevalence than non OSA women even after adjustment for BMI and WHR. Among M women, those with OSA were more frequently hypertensive and had higher CRP levels and similar glucose tolerance than non OSA women. ([Table 1](#pone-0061382-t001){ref-type="table"}). The adjustment for BMI nullified the difference in CRP levels.

The proportion of hypersonnolence was not significantly higher in OSA than in non OSA women (in PM women 33 vs 14% and in M women 0% vs 20%, NS).

Relationships between Nocturnal Polysomnographic Data and Clinical and Biochemical Variables {#s3a}
--------------------------------------------------------------------------------------------

[Table 2](#pone-0061382-t002){ref-type="table"} shows the univariate correlations in the whole group of obese women. AHI, ODI and nocturnal SaO~2~ were significantly correlated with age and with all obesity indexes. Nocturnal mean and min SaO2 were associated with NHR, independently of the other obesity indexes (BMI, WHR and fat mass/fat-free mass) and age.

10.1371/journal.pone.0061382.t002

###### Correlation coefficients of nocturnal respiratory registration data with obesity indexes, insulin sensitivity and fasting glucose in 98 obese women.

![](pone.0061382.t002){#pone-0061382-t002-2}

                         Age              BMI               WHR               NHR             FM/FFM             FPG              2 hPG              ISI
  ----------- --- ----------------- ---------------- ----------------- ----------------- ---------------- ----------------- ----------------- -----------------
  AHI          r   **.283^\*\*^**     **.259^\*^**         .211          **.258^\*^**      **.228^\*^**         .067              .032              −.119
               p        .008              .015             .052              .017              .033             .533              .768              .292
  ODI          r   **.274^\*\*^**    **.281^\*\*^**    **.217^\*^**      **.244^\*^**          .192             .111              .093              −.129
               p        .006              .005             .034              .018              .058             .276              .361              .224
  Mean SaO2    r   −**.456^\*\*^**       −.184        −**.337^\*\*^**   −**.349^\*\*^**       −.113        −**.306^\*\*^**        −.183        **.282^\*\*^**
               p        .000              .070             .001              .001              .268             .002              .072              .007
  Min SaO2     r   −**.359^\*\*^**   −**.244^\*^**         −.188         −**.263^\*^**        −.155         −**.200^\*^**         −.155         **.226^\*^**
               p        .000              .015             .068              .010              .128             .048              .127              .032
  BMI          r        −.197              1          **.529^\*\*^**    **.403^\*\*^**    **.504^\*\*^**        .059              .108          −**.267^\*^**
               p        .051                               .000              .000              .000             .563              .288              .011
  WHR          r   **.306^\*\*^**    **.529^\*\*^**          1          **.514^\*\*^**    **.358^\*\*^**        .119              .122          −**.260^\*^**
               p        .003              .000                               .000              .000             .249              .239              .015
  NHR          r   **.311^\*\*^**    **.403^\*\*^**   **.514^\*\*^**           1               .098        **.283^\*\*^**     **.219^\*^**     −**.404^\*\*^**
               p        .002              .000             .000                                .347             .006              .034              .000
  FM/FFM       r        −.021        **.504^\*\*^**   **.358^\*\*^**         .098               1               .003              .046              .003
               p        .837              .000             .000              .347                               .979              .653              .977
  FPG          r   .**327^\*\*^**         .059             .119         **.283^\*\*^**         .003               1          **.585^\*\*^**    −**.466^\*\*^**
               p        .001              .563             .249              .006              .979                               .000              .000
  2 hPG        r    **.214^\*^**          .108             .122          **.219^\*^**          .046        **.585^\*\*^**           1          −**.455^\*\*^**
               p        .035              .288             .239              .034              .653             .000                                .000
  ISI          r        −.148        −**.267^\*^**     −**.260^\*^**    −**.404^\*\*^**        .003        −**.466^\*\*^**   −**.455^\*\*^**          1
               p        .165              .011             .015              .000              .977             .000              .000        

BMI: body mass index; WHR: waist/height ratio; NHR: neck/height ratio; FM/FFM: fat mass/fat free mass ratio; FPG: fasting glucose; 2 h PG: 2 h glucose; ISI: insulin sensitivity index; AHI: Apnea-Hypopnea Index; ODI: Oxygen Desaturation Index; mean SaO~2~: mean nocturnal oxygen saturation; min SaO~2~: minimal nocturnal oxygen saturation.

Both nocturnal mean and minimal SaO~2~ and NHR were correlated with ISI and fasting glucose.

In the multivariate analysis with ISI as dependent variable and BMI, WHR, NHR, mean and minimal nocturnal SaO~2~ as independent variables, only NHR remained independently associated with ISI (β −0.404, p\<0.0001). In a model with fasting glucose as dependent variable and age, WHR, NHR, mean and minimal nocturnal SaO2 as independent variables, only mean nocturnal SaO~2~ remained independently associated with fasting glucose (β −0.310, p\<0.0001).

No relations were found between nocturnal polisomnographic data and ESS score, CRP, BP and insulinogenic index. Systolic BP was correlated with age (0.225, p\<0.05), NHR, WHR and ISI (r 0.246, r 0.236 and r −0.212, p\<0.05 for all), however after controlling for age these relations became not significant.

Effects of Lifestyle Intervention in 54 Obese Women with OSA {#s3b}
------------------------------------------------------------

After 3 months of lifestyle intervention, obese women with OSA (16 PM and 38 M) reduced their weight by 4.8±2.7% (p\<0.0001). This was associated with significant reduction of WHR, NHR and BP, improvement in body composition, insulin sensitivity and β cell function and increase in minimal nocturnal SaO~2~ ([Figure 1](#pone-0061382-g001){ref-type="fig"}). Remission of OSA (AHI \<5) was observed in 23% of women. AHI decreased by 17% and ODI by 14%, but these changes were not statistically significant probably because of a high individual variability.

![Relative changes in anthropometric, metabolic and nocturnal registration respiratory data in 54 non diabetic obese women with OSA after lifestyle intervention.\
BMI: body mass index; WHR: waist/height ratio; FM/FFM: fat mass/fat free mass ratio; NHR: neck/height ratio; FPG: fasting glucose; ISI: insulin sensitivity index; ΔI~30~/ΔG~30:~ insulinogenic index; sBP: systolic blood pressure; dBP: diastolic blood pressure; HR: heart rate; CRP: C-reactive protein; min SaO~2~: minimal nocturnal oxygen saturation; AHI: Apnea-Hypopnea Index; ODI: Oxygen Desaturation Index. Data are expressed as mean±ES. \*\*\*p\<0.0001, \*\*p\<0.001, \*p\<0.05.](pone.0061382.g001){#pone-0061382-g001}

The effect of lifestyle intervention on polysomnographic data was independent of age and baseline values of nocturnal respiratory data, obesity indexes and cardio metabolic variables.

Changes in minimal nocturnal SaO~2~ were correlated with those in weight and fat mass/fat free mass (r −0.273 and r −0.367, p\<0.05). Changes in ISI and fasting glucose were associated with those in minimal nocturnal SaO~2~ (r 0.400, r −0.324, p\<0.05 for both) and not with those of all obesity indexes.

Discussion {#s4}
==========

Our study provides evidence that 1) in non diabetic obese women, OSA is frequent also before menopausal status where it is associated with alterations of glucose homeostasis, 2) lower nocturnal mean SaO~2~ and higher neck circumference have additive effects in the worsening of glucose tolerance, 3) a modest weight reduction is able to normalize the nocturnal breathing pattern in approximately one quarter of OSA women, 4) in OSA women, the lifestyle intervention-induced increase in minimal nocturnal SaO~2~ is associated with the improvement of glucose tolerance~.~

The frequency of OSA we found in PM women was comparable to the 40% observed in severely obese PM women in a Norwegian obesity center [@pone.0061382-Fredheim1]. This prevalence was about four fold higher than that estimated in US obese women of similar age using the same definition of OSA (11%) [@pone.0061382-Young2] likely because general population was the setting of recruitment in the U.S. study.

The novel result of the present study is that glucose homeostasis worsens in the presence of OSA more clearly in PM than in M women. This finding is in agreement with the previous demonstration that OSA prevalence significantly increases with the worsening of glucose tolerance in PM but not in M women [@pone.0061382-Foster1]. The association of menopause with worse glucose tolerance in non OSA group together with the comparable glucose tolerance in OSA and non OSA.

M women, suggests that the negative effect on glucose tolerance exerted by increasing age [@pone.0061382-DeFronzo1] might have masked a possible additive effect of OSA on glucose homeostasis.

The results of our study support the deleterious effects of nocturnal hypoxia on glucose tolerance. Acute hypoxemia and prolonged exposure to high altitude hypobaric hypoxia alter glucose metabolism in healthy subjects [@pone.0061382-Oltmanns1], [@pone.0061382-Larsen1]. Further, glucose tolerance is impaired in patients with chronic obstructive pulmonary disease and improves with oxygen supplementation [@pone.0061382-Jakobsson1].

Relatively few studies investigated the relationships between nocturnal respiratory data and metabolic variables. Insulin and glucose levels were found associated with AHI and/or ODI and/or nocturnal SaO~2~ but this was often dependent on obesity [@pone.0061382-Bulcun1], [@pone.0061382-Elmasry1]--[@pone.0061382-Kapsimalis1]. In the only study available in women, low nocturnal minimal SaO~2~ was associated with decreased insulin sensitivity and higher glucose levels independently on waist/hip ratio in overweight women aged 20--70 years [@pone.0061382-TheorellHaglw1].

Hypoxemia is an important stimulus for increasing sympathetic activity which in turn can impair glucose homeostasis by increasing glycogen breakdown and gluconeogenesis and for releasing inflammatory factors with deleterious effects on insulin synthesis and peripheral action [@pone.0061382-Punjabi1]. The independent relation we found between meanSaO2 and fasting glucose suggests that nocturnal hypoxia may increase glucose levels not only by worsening insulin sensitivity but also exerting a direct hyperglycemic effect. In support of this hypothesis, it had been demonstrated that in humans, a physiological increase in epinephrine concentration induces a sustained and biphasic increase in glucose production independent of changes in plasma insulin concentrations [@pone.0061382-Dufour1].

The reason why nocturnal hypoxia severity is more important than the frequency of nocturnal desaturations in determining glucose homeostasis alterations has yet to be defined.

We observed a negative and independent relation of NHR with insulin sensitivity in accord with what reported in the Framingham Heart Study [@pone.0061382-Preis1]. This finding suggests that an increased neck circumference may contribute to impair glucose tolerance. The mechanism by which a greater neck circumference could worsen insulin sensitivity may be the mechanical compression of the upper airway with consequent induction of nocturnal hypoxia and/or the overproduction of free fatty acids. Neck circumference indeed is a surrogate measure of upper-body subcutaneous adipose tissue which is responsible for a much larger proportion of systemic free fatty acid release than visceral fat, particularly in obese individuals [@pone.0061382-Nielsen1] and in women who store larger proportions of free fatty acids than men in subcutaneous adipose tissue [@pone.0061382-Preis1], [@pone.0061382-Koutsari1].

We demonstrated that a lifestyle intervention is able to normalize in a short time the nocturnal respiratory pattern in nearly a quarter of obese women with mild OSA. We observed a relation between changes in obesity and in minimal nocturnal SaO~2~ but not in AHI. This result agrees with those of most dietary intervention studies and is likely due to the large individual variability in AHI changes [@pone.0061382-Anandam1]. Notably, AHI decreased of the same magnitude (14%) reported in subjects who experienced a 5% weight loss in a 4-years observational study [@pone.0061382-Peppard1]. As observed in previous studies, AHI changes were unrelated to those of metabolic variables [@pone.0061382-Tuomilehto1], [@pone.0061382-Nerfeldt1] whereas changes in minimal SaO2 were associated with changes in glycaemia and insulin sensitivity. The demonstration that in the obese OSA women investigated in this study, the improvement in glucose tolerance was not related to the reduction of obesity, supports the hypothesis that the decrease of nocturnal hypoxia is the mediator of the weight loss induced improvement of glucose tolerance in OSA women.

In conclusion in obese women, glucose homeostasis worsens due to the additive effects of nocturnal hypoxia and increased neck circumference through mechanisms partially independent of obesity (sympathetic activation and mechanical narrowing of the upper airway). OSA is more clearly associated with glucose intolerance in premenopausal than in menopausal women. In OSA women, the improvement of nocturnal hypoxia induced by lifestyle modifications is associated with that of glucose homeostasis.
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